SCHEMBL8744184

SCHEMBL8744184

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=S)Oc2ccccc2)[C@@H](O)[C@H]1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.66
GSK3A P49840 2/20 0.65
RPS6KA3 P51812 2/20 0.65
MAPK14 Q16539 2/20 0.65
SMN1; SMN2 Q16637 3/20 0.61
ADORA3 P0DMS8 2/20 0.61
ADORA2A P29274 2/20 0.61
ADORA2B P29275 2/20 0.61
DPP4 P27487 1/20 0.61
MEN1 O00255 1/20 0.61
SLC28A1 O00337 1/20 0.61
MAP3K7 O43318 1/20 0.61
SLC28A2 O43868 1/20 0.61
GAPDH P04406 1/20 0.61
MAPK1 P28482 1/20 0.61
STAT6 P42226 1/20 0.61
PI4KA P42356 1/20 0.61
KMT2A Q03164 1/20 0.61
PI4K2B Q8TCG2 1/20 0.61
DOT1L Q8TEK3 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235451 0.90 GSK3A (0.67) ADORA1GSK3ARPS6KA3MAPK14SMN1; SMN2
SCHEMBL1434032 0.88 ADORA1 (0.72) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL6905464 0.88 ADORA1 (0.72) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL9387983 0.85 ADORA1 (0.66) ADORA1GSK3ARPS6KA3MAPK14SMN1; SMN2
SCHEMBL11644877 0.84 ABCB1 (0.77) ADORA1GSK3ARPS6KA3MAPK14SMN1; SMN2
SCHEMBL441535 0.84 ABCB1 (0.77) ADORA1GSK3ARPS6KA3MAPK14SMN1; SMN2
SCHEMBL1757017 0.83 ADORA1 (0.73) ADORA1GSK3ARPS6KA3MAPK14SMN1; SMN2
SCHEMBL19859780 0.83 ADORA1 (0.73) ADORA1GSK3ARPS6KA3MAPK14SMN1; SMN2
SCHEMBL2835895 0.82 METTL3 (0.65) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL2835899 0.82 METTL3 (0.65) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0753002-A1 MODIFIED OLIGONUCLEOTIDES AND INTERMEDIATES USEFUL IN NUCLEIC ACID THERAPEUTICS AMGEN INC. (US) 1997-01-15 EP disclosed
WO-1995026972-A1 MODIFIED OLIGONUCLEOTIDES AND INTERMEDIATES USEFUL IN NUCLEIC ACID THERAPEUTICS AMGEN INC. (US) 1995-10-12 WO disclosed